United Services Automobile Association bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $697,000.
Several other large investors also recently added to or reduced their stakes in the stock. Van ECK Associates Corp raised its position in Jazz Pharmaceuticals PLC by 133.0% in the first quarter. Van ECK Associates Corp now owns 60,049 shares of the specialty pharmaceutical company’s stock worth $8,715,000 after buying an additional 34,276 shares during the last quarter. BB&T Securities LLC acquired a new position in Jazz Pharmaceuticals PLC during the first quarter worth approximately $279,000. Alliancebernstein L.P. raised its position in Jazz Pharmaceuticals PLC by 19.4% in the first quarter. Alliancebernstein L.P. now owns 4,211 shares of the specialty pharmaceutical company’s stock worth $611,000 after buying an additional 684 shares during the last quarter. Fort Washington Investment Advisors Inc. OH acquired a new position in Jazz Pharmaceuticals PLC during the first quarter worth approximately $722,000. Finally, Vident Investment Advisory LLC acquired a new position in Jazz Pharmaceuticals PLC during the first quarter worth approximately $325,000. 86.28% of the stock is owned by institutional investors.
Jazz Pharmaceuticals PLC (JAZZ) traded up 0.17% during mid-day trading on Tuesday, hitting $161.25. The company had a trading volume of 348,406 shares. The firm has a market capitalization of $9.68 billion, a PE ratio of 24.37 and a beta of 1.11. The company has a 50 day moving average of $154.34 and a 200 day moving average of $143.86. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing analysts’ consensus estimates of $1.42 by $0.01. The business had revenue of $376.10 million during the quarter, compared to the consensus estimate of $376.58 million. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $2.26 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post $11.01 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “United Services Automobile Association Invests $697,000 in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/07/25/united-services-automobile-association-acquires-shares-of-4800-jazz-pharmaceuticals-plc-jazz-updated-updated.html.
A number of research firms have commented on JAZZ. Zacks Investment Research lowered Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Royal Bank Of Canada set a $210.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, June 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $197.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, June 27th. Cowen and Company reaffirmed an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, May 10th. Finally, Leerink Swann set a $179.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $182.56.
In related news, CEO Bruce C. Cozadd sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $153.47, for a total value of $4,604,100.00. Following the completion of the transaction, the chief executive officer now owns 296,418 shares of the company’s stock, valued at $45,491,270.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $160.00, for a total transaction of $400,000.00. Following the completion of the transaction, the executive vice president now directly owns 39,649 shares of the company’s stock, valued at approximately $6,343,840. The disclosure for this sale can be found here. Insiders sold 46,875 shares of company stock valued at $7,249,820 in the last three months. 4.30% of the stock is currently owned by insiders.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com’s FREE daily email newsletter.